Astrazeneca Share Price (AZN)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-12.00	-0.19%	6,390.00	1,748,232	16:35:17

Bid Price		Offer Price	High Price	Low Price	Open Price
6,376.00		6,379.00	6,454.00	6,359.00	6,420.00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	17,322.09	1,562.83	133.31	47.0	83,823

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
17:52:07	O	2,206	6,390.00	GBX

Related Shares
Glaxosmithkline (GSK), Hikma Pharmaceuticals (HIK), Bermele (BERM), Valirx (VAL)

Astrazeneca (AZN) Latest News

Astrazeneca News

Date	Time	Source	Headline
15/7/2019	09:10	ALNC	TOP NEWS: Astra's Farxiga Fails To Get US Approval For Type-1 Diabetes
15/7/2019	07:08	ALNCF	Alliance News Flash Headline
15/7/2019	07:00	UKREG	AstraZeneca PLC Update on US regulatory decision for Farxiga
12/7/2019	08:56	ALNC	TOP NEWS: AstraZeneca Gets US FDA Orphan Drug Designation For Imfinzi
12/7/2019	07:46	DJN	AstraZeneca: Imfinzi Granted US Orphan Drug Designation
12/7/2019	07:00	UKREG	AstraZeneca PLC Imfinzi granted US Orphan Drug Designation for
01/7/2019	15:00	UKREG	AstraZeneca PLC Total Voting Rights
01/7/2019	08:56	ALNC	AstraZeneca Gets Positive EU Committee Opinion On Forixga And Fasenra
01/7/2019	07:00	UKREG	AstraZeneca PLC Fasenra receives positive EU CHMP opinion for self
27/6/2019	10:55	ALNC	Encouraging Interim Analysis From Trial Of AstraZeneca Drug Imfinzi

More Astrazeneca News

Astrazeneca Takeover Rumours

Astrazeneca (AZN) Share Charts

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

Intraday Astrazeneca Chart

Astrazeneca (AZN) Discussions and Chat

Astrazeneca Forums and Chat

Date	Time	Title	Posts
12/7/2019	08:09	Alzheimer's can be caught .... It's a transmissible disease	95
03/7/2019	21:52	AstraZeneca	2,188
01/5/2019	19:48	why the fall	-
13/2/2019	11:48	AstraZeneca Full Year Results on Thursday	-
15/10/2018	18:31	* AstraZeneca *	360

Add a New Thread

Astrazeneca (AZN) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Astrazeneca trades in real-time

Astrazeneca (AZN) Top Chat Posts

Date	Subject
21/7/2019 09:20	Astrazeneca Daily Update: Astrazeneca Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 6,402p. Astrazeneca Plc has a 4 week average price of 6,291p and a 12 week average price of 5,626p. The 1 year high share price is 6,634p while the 1 year low share price is currently 5,312p. There are currently 1,311,776,898 shares in issue and the average daily traded volume is 1,677,635 shares. The market capitalisation of Astrazeneca Plc is £83,822,543,782.20. Read Full Thread Reply
18/6/2019 13:01	bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth. Read Full Thread Follow Reply
18/7/2018 12:01	bountyhunter: http://uk.advfn.com/stock-market/london/astrazeneca-AZN/share-news/AstraZeneca-Increases-Drug-Stockpile-in-Preparatio/77885692 that's one way to reduce any potential initial WTO tariffs/bottlenecks! Read Full Thread Follow Reply
08/10/2017 12:51	cool druid: [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance \| Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment Read Full Thread Follow Reply
30/7/2017 19:12	nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend." Read Full Thread Follow Reply
28/7/2017 15:10	minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh? Read Full Thread Follow Reply
27/7/2017 10:46	minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675. Read Full Thread Follow Reply
27/7/2017 10:10	steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend. Read Full Thread Follow Reply
27/1/2017 09:02	steeplejack: Goldmans issued a sell note on the 24 Jan with a £39 share price target.Thats probably still washing through. Read Full Thread Follow Reply
20/1/2017 17:26	philanderer: "Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? 'Patience' AstraZeneca is Woodford's largest holding and an example of just how long he's prepared to be patient with a company he views as intrinsically undervalued. Earnings at the pharma group have suffered as a result of expiring patents on some of its top sellers and no improvement is expected to the bottom line until 2018. However, the company has maintained its dividend through this difficult period and offers a 5% yield at a current share price of around 4,400p. The dividend is forecast to start rising with the resumption of earnings growth in 2018 as a result of Astra's reinvigorated drugs pipeline. HTTP://money.aol.co.uk/2017/01/20/is-neil-woodford-a-fool-to-continue-pumping-money-into-capita-pl/ Read Full Thread Follow Reply
02/5/2014 08:43	harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on . Read Full Thread Follow Reply

Astrazeneca share price data is direct from the London Stock Exchange

Your Recent History

LSE

AZN

Astrazenec..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190721 19:46:34